Bibliographic Details
| Title: |
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, random ised controlled trial. |
| Authors: |
Yung-Jue Bang, Young-Woo Kim, Han-Kwang Yang, Hyun Cheol Chung, Young-Kyu Park, Kyung Hee Lee, Keun-Wook Lee, Yong Ho Kim, Sang-Ik Noh, Joe Yong Cho, Young Joe Mok, Yeul Hong Kim, Jiafu Ji, Ta-Sen Yeh, Button, Peter, Sirzén, Florin, Sung Hoon Noh |
| Source: |
Lancet. 1/28/2012, Vol. 379 Issue 9813, p315-321. 7p. |
| Subjects: |
Adjuvant treatment of cancer, Oxaliplatin, Germfree life, Survival analysis (Biometry), Gastrectomy, Stomach cancer patients |
| Abstract: |
The article presents a study which examines the effect of adjuvant chemotherapy with capecitabine plus oxaliplatin in the disease-free survival following D2 gastrectomy. The study randomly subjected stage II-IIIB gastric cancer patients, who undergone curative D2 gastrectomy, to adjuvant chemotherapy with oral capecitabine and intravenous oxaliplatin treatment or surgery only. Result shows that chemotherapy patients have 74% of 3 year disease-free survival, while surgery only patients show 59%. |
| Database: |
Psychology and Behavioral Sciences Collection |
